Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036572 (
seizures
)
80,221
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Epileptic seizures are frequent in patients with glioma, and anticonvulsive treatment is often indicated. Glioma cells release glutamate via the X
c
- antiporter system, which appears to be a major pathomechanism of glioma-associated
seizures
and excitotoxicity. In addition, the proliferation and survival of the tumor cells are promoted. Therefore, anticonvulsants that attenuate glutamate-mediated receptor activation could be especially effective. In this study, we investigated the effects of AMPA receptor antagonist perampanel in rat C6 glioma model. In first pilot experiments, perampanel reduced glucose uptake but had no impact of extracellular glutamate level in vitro. To analyze the effects of perampanel in vivo, we injected C6 cells orthotopically into the neocortex of Wistar rats in order to establish a model of glioma-associated epilepsy. Spontaneous recurrent discharges in brain slices were abolished upon perfusion with the AMPA receptor blocker perampanel, supporting the major role of glutamatergic excitation. With respect to the
tumor progression
, no effect of perampanel on survival of the animals or on glioma size was determined. Our data demonstrate that perampanel inhibit epileptiform discharges in organotypic brain slices of glioma, but failed to attenuate tumor growth or promote animal survival.
...
PMID:Perampanel attenuates epileptiform phenotype in C6 glioma. 3173 90
More than one-third of patients with meningiomas will experience
seizures
at some point in their disease. Despite this, meningioma-associated epilepsy remains significantly understudied, as most investigations focus on
tumor progression
, extent of resection, and survival. Due to the impact of epilepsy on the patient's quality of life, identifying predictors of preoperative
seizures
and postoperative
seizure
freedom is critical. In this chapter, we review previously reported rates and predictors of
seizures
in meningioma and discuss surgical and medical treatment options. Preoperative epilepsy occurs in approximately 30% of meningioma patients with peritumoral edema on neuroimaging being one of the most significant predictor of
seizures
. Other associated factors include age <18, male gender, the absence of headache, and non-skull base tumor location. Following tumor resection, approximately 70% of individuals with preoperative epilepsy achieve
seizure
freedom. Variables associated with persistent
seizures
include a history of preoperative epilepsy, peritumoral edema, skull base tumor location,
tumor progression
, and epileptiform discharges on postoperative electroencephalogram. In addition, after surgery, approximately 10% of meningioma patients without preoperative epilepsy experience new
seizures
. Variables associated with new postoperative
seizures
include
tumor progression
, prior radiation exposure, and gross total tumor resection. Both pre- and postoperative meningioma-related
seizures
are often responsive to antiepileptic drugs (AEDs), although AED prophylaxis in the absence of
seizures
is not recommended. AED selection is based on current guidelines for treating focal
seizures
with additional considerations including efficacy in tumor-related epilepsy, toxicities, and potential drug-drug interactions. Continued investigation into medical and surgical strategies for preventing and alleviating epilepsy in meningioma is warranted.
...
PMID:Seizures in meningioma. 3258 90
<< Previous
1
2
3
4
5
6
7